drugset / Trial / NCT07164560
Exploratory Study of Umbilical Cord Blood-Derived CAR-NK Cell Therapy Targeting TRBC1/2 for Relapsed/Refractory T-Cell Lymphoma
Phase 1
Recruiting
45 enrolled
Second Affiliated Hospital, School of Medicine, Zhejiang University
Peking University Cancer Hospital & Institute · collab
NaSingle-groupOpen-labelTreatment
Summary
This study aims to evaluate the safety and efficacy of Umbilical Cord Blood-Derived CAR-NK Cell Therapy Targeting TRBC1/2 (TRBC1/2 CAR-NK cells) in patients with refractory or relapsed peripheral T-cell lymphoma (PTCL).
Timeline
- Start
- 2026-04-01
- Primary completion
- 2029-01-01
- Completion
- 2029-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TRBC1/2 CAR-NK cells | Cell therapy | — | Intravenous |